From monoamines to genomic targets: A paradigm shift for drug discovery in depression

Nature Reviews Drug Discovery

Volumn 3, Issue 2, 2004, Pages 136-151

  Wong, Ma Li ^a   Licinio, Julio ^a  

^a Neuropsychiatric Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; APREPITANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRONIAZID; MILNACIPRAN; MIRTAZAPINE; MONOAMINE; NEUROHORMONE; NEUROPEPTIDE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; REBOXETINE; SELEGILINE; SERTRALINE; SUBSTANCE P; TIANEPTINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; CONSTIPATION; DIFFERENTIAL DISPLAY; DNA MICROARRAY; DROWSINESS; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ENERGY; ENVIRONMENTAL FACTOR; GENOTYPE ENVIRONMENT INTERACTION; HEART PALPITATION; HEREDITY; HUMAN; HYPERTENSIVE CRISIS; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MONOAMINERGIC SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; SEXUAL DYSFUNCTION; SIDE EFFECT; XEROSTOMIA;

EID: 1242263295     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1303     Document Type: Review

References (205)

1. Bloch, R. G. et al. The clinical effects of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann. Intern. Med. 40, 881-900 (1954).
2. Keith, S. J. & Matthews, S. M. The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol. Bull. 29, 427-430 (1993).
3. Moller, H. J. & Volz, H. P. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 52, 625-638 (1996).
4. Blazer, D. G., Kessler, A. C., McGonagle, K. A. & Swartz, M. S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151, 979-986 (1994).
5. Greenber, P. E. et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64, 1465-1475 (2003).
6. Pincus, H. A. & Pettit, A. R. The societal costs of chronic major depression. J. Clin. Psychiatry 62 (Suppl. 6), 5-9 (2001).
7. Healy, D. The Antidepressant Era (Harvard Univ. Press, Cambridge, 1997).
8. Loomer, H. P., Saunders, J. C. & Kline, N. S. A Clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr. Res. Rep. Am. Psychiatr. Assoc. 8, 129-141 (1957).
9. Kuhn, R. Uber die behandlung depressives zustande mit einem iminobenzylderivat (G 22,355). Schweiz. Med. Wochenschr. 87, 1135-1140 (1957).
10. Glowinski, J., Axelrod, J., Kopin, I. J. & Wurtman, R. J. Physiological disposition of H3-norepinephrine in the developing rat. J. Pharmacol. Exp. Ther. 146, 48-53 (1964).
11. Carlsson, A., Lindqvist, M. & Waldeck, B. Mechanism of release of alpha-methylated noradrenaline analogues by monoamine oxidase inhibitors. Eur. J. Pharmacol. 3, 34-39 (1968).
12. Broekkamp, C. L., Leysen, D., Peeters, B. W. & Pinder, R. M. Prospects for improved antidepressants. J. Med. Chem. 38, 4615-4633 (1995).
13. Kent, J. M. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355, 911-918 (2000).
14. Anderson, I. M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety 7 (Suppl 1), 11-17 (1998).
15. Thase, M. E., Entsuah, A. R. & Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
16. Entsuah, A. R., Huang, H. & Thase, M. E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869-877 (2001).
17. Bymaster, F. P., McNamara, R. K. & Tran, P. V. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin. Investig. Drugs 12, 531-543 (2003).
18. Selye, H. A syndrome produced by diverse nocuous agents. Nature 138, 32 (1936).
19. Chrousos, G. P. & Gold, P. W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267, 1244-1252 (1992).
20. Gold, P. W., Wong, M. L., Chrousos, G. P. & Licinio, J. Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Mol. Psychiatry 1, 257-264 (1996).
21. Brady, L. S., Whitfield, H. J. Jr, Fox, R. J., Gold, P. W. & Herkenham, M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 87, 831-837 (1991).
22. Brady, L. S., Gold, P. W., Herkenham, M., Lynn, A. B. & Whitfield, H. J. Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572, 117-125 (1992).
23. Michelson, D. et al. Chronic imipramine is associated with diminished hypothalamic pituitary-adrenal axis responsivity in healthy humans. J. Clin. Endocrinol. Metab. 82, 2601-2606 (1997).
24. Nemeroff, C. B. et al. Elevated concentrations of CSF corticotropin-releasing-factor-like immunoreactivity in depressed patients. Science 226, 1342-1344 (1984).
25. Wong, M. L. et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Pros. Natl Acad. Sci. USA 97, 325-330 (2000).
26. Gold, P. W. et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am. J. Psychiatry 141, 619-627 (1984).
27. Gold, P. W. et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N. Engl. J. Med. 314, 1329-1335 (1986).
28. Hiroi, N. et al. Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol. Psychiatry 6, 540-546 (2001).
29. Raadsheer, F. C., Hoogendijk, W. J., Stam, F C., Tilders, F. J. & Swaab, D. F. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60, 436-444 (1994).
30. Habib, K. E. et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl Acad. Sci. USA 97, 6079-6084 (2000).
31. Zobel, A. W. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34, 171-181 (2000).
32. Whybrow, P. C. & Prange, A. J. Jr. A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch. Gen. Psychiatry 38, 106-113 (1981).
33. Gold, P. W. & Chrousos, G. P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc. Assoc. Am. Physicians 111, 22-34 (1999).
34. Joffe, R. T. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J. Psychiatry Neurosci. 22, 327-331 (1997).
35. Vaupel, R., Jarry, H., Schlomer, H. T. & Wuttke, W. Differential response of substance P-containing subtypes of adrenomedullary cells to different stressors. Endocrinology 123, 2140-2145 (1988).
36. Coiro, V. et al. Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: inhibition by sodium valproate. Neuroendocrinology 56, 459-463 (1992).
37. Kramer, M. S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645 (1998).
38. Ranga, K. & Krishnan, R. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiatry 63 (Suppl 11), 25-29 (2002).
39. Argyropoulos, S. V. & Nutt, D. J. Substance P antagonists: novel agents in the treatment of depression. Expert Opin. Investig. Drugs 9, 1871-1875 (2000).
40. Campos, D. et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19, 1759-1767 (2001).
41. New drug helps relieve chemotherapy-related symptoms. FDA Consum. 37, 3 (2003).
42. Holsboer, F. Corticotropin-releasing hormone modulators and depression, Curr. Opin. Investig. Drugs 4, 46-50 (2003).
43. Peterson, L. & Weber, M.S. Report of the American Psychiatric Association meeting 2002. [online], (cited 13 Jan 2003) (2002).
44. Nemeroff, C. B. & Owens, M. J. Treatment of mood disorders. Nature Neurosci. 5, S1068-S1070 (2002).
45. McEwen, B. S. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 22, 105-122 (1999).
46. Lewin, R. Clinical trial for Parkinson's disease? Science 230, 527-528 (1985).
47. Shoulson, I. et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. 51, 604-612 (2002).
48. Sivenius, J. et al. Selegiline treatment facilitates recovery after stroke. Neurorehabil. Neural Repair 15, 183-190 (2001).
49. van der Hart, M. G. et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol. Psychiatry 7, 933-941 (2002).
50. Duman, R. S., Mallberg, J., Nakagawa, S. & D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry 48, 732-739 (2000).
51. Smith, M. A., Makino, S., Kvetnansky, R. & Post, R. M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15, 1768-1777 (1995).
52. Nibuya, M., Morinobu, S. & Duman, R. S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15, 7539-7547 (1995).
53. Siuciak, J. A., Lewis, D. R., Wiegand, S. J. & Lindsay, R. M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56, 131-137 (1997).
54. Malberg, J. E., Eisch, A. J., Nestler, E. J. & Duman, R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104-9110 (2000).
55. Malberg, J. E. & Duman, R. S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28, 1562-1571 (2003).
56. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
57. Licinio, J. & Wong, M. L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 4, 317-327 (1999).
58. Connor, T. J. & Leonard, B. E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62, 583-606 (1998).
59. Berkenbosch, F., van Oers, J., del Rey, A., Tilders, F. & Besedovsky, H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238, 524-536 (1987).
60. Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P. & Vale, W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin releasing factor. Science 238, 522-524 (1987).
61. Zorrila, E. P. et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15, 199-226 (2001).
62. Maes, M. et al. Higher α1-antitrypsin, haptoglobin, ceruloplasmin and lower retinal binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J. Affect. Disord. 24, 183-192 (1992).
63. Song, C., Dinan, T. & Leonard, B. E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 30, 283-288 (1994).
64. Connor, T. J., Kelly, J. P. & Leonard, B. E. Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol. Biochem. Behav. 59, 171-177 (1998).
65. Castanon, N., Leonard, B. E., Neveu, P. J. & Yirmiya, R. Effects of antidepressants on cytokine production and actions. Brain Behav. Immun. 16, 569-574 (2002).
66. Leonard, B. E. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 767-780 (2001).
67. Rott, R. et al. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science 228, 755-756 (1985).
68. Bode, L., Zimmermann, W., Ferszt, R., Steinbach, F. & Ludwig, H. Borna disease virus genome transcribed and expressed in psychiatric patients. Nature Med. 1, 232-236 (1995).
69. Bode, L., Durrwald, R., Rantam, F. A., Ferszt, R. & Ludwig, H. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol. Psychiatry 1, 200-212 (1996).
70. Schwaninger, M., Schofl, C., Blume, R., Rossig, L. & Knepel, W. Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/cyclic AMP response element-directed gene transcription. Mol. Pharmacol. 47, 1112-1118 (1995)
71. Sassone-Corsi, P. Transcription factors responsive to cAMP. Annu. Rev. Cell Dev. Biol. 11, 355-377 (1995).
72. Schulman, H. Protein phosphorylation in neuronal plasticity and gene expression. Curr. Opin. Neurobiol. 5, 375-381 (1995).
73. Bourtchuladze, R. et al. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 79, 59-68 (1994).
74. Manier, D. H., Shelton, R.C. & Sulser, F. Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P? J. Neural Transm. 109, 91-99 (2002).
75. Nibuya, M., Nestler, E. J. & Duman, R. S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16, 2365-2372 (1996).
76. Newton, S. S. et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 22, 10883-10890 (2002).
77. Shaywitz, A. J. & Greenberg, M. E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821-861 (1999).
78. Shirayama, Y., Chen, A. C., Nakagawa, S., Russell, D. S. & Duman, R. S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22, 3251-3261 (2002).
79. Borsook, D., Konradi, C., Falkowski, C., Comb, M. & Hyman, S. E. Molecular mechanisms of stress-induced proenkephalin gene regulation: CREB interacts with the proenkephalin gene in the mouse hypothalamus and is phosphorylated in response to hyperosmolar stress. Mol. Endocrinol. 8, 240-248 (1994).
80. Cole, R. L., Konradi, C., Douglass, J. & Hyman, S. E. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14, 813-823 (1995).
81. Carlezon, W. A. Jr et al. Regulation of cocaine reward by CREB. Science 282, 2272-2275 (1998).
82. Pare, C. M., Rees, L. & Sainsbury, M. J. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 2, 1340-1343 (1962).
83. Licinio, J. & Wong, M. L. The pharmacogenomics of depression. Pharmacogenomics J. 1, 175-177 (2001).
84. Smeraldi, E. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3, 508-511 (1998).
85. Wong, M. L., Khatri, P., Licinio, J., Esposito, A. & Gold, P. W. Identification of hypothalamic transcripts unregulated by antidepressants. Biochem. Biophys. Res. Commun. 229, 275-279 (1996).
86. Landgrebe, J. et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J. Psychiatr. Res. 36, 119-129 (2002).
87. Yamada, M. et al. Differential expression of VAMPs/synaptobrevin-2 after antidepressant and electroconvulsive treatment in rat frontal cortex. Pharmacogenomics J. 2, 377-382 (2003).
88. Reti, I. M. & Baraban, J. M. Sustained increase in Narp protein expression following repeated electroconvulsive seizure. Neuropsychopharmacology 23, 439-443 (2000).
89. Johansson, I. M. et al. Chronic amitriptyline treatment induces hippocampal NGFI-A, glucocorticoid receptor and mineralocorticoid receptor mRNA expression in rats. Brain Res. Mol. Brain Res. 62, 92-95 (1998).
90. Torres, G., Horowitz, J. M., Laflamme, N. & Rivest, S. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neuroscience 87, 463-477 (1998).
91. Bjartmar, L. et al. Selective effects on NGFI-A, MR, GR and NGFI-B hippocampal mRNA expression after chronic treatment with different subclasses of antidepressants in the rat. Psychopharmacology (Berl) 151, 7-12 (2000).
92. Thome, J. et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 4030-4036 (2000).
93. Chen, J. et al. Regulation of δ FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol. Pharmacol. 48, 880-889 (1995).
94. Wong, M.-L. et al. St. John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol. Psychiatry 13 Jan 2004 (doi: 10. 1038/sj.mp.4001470).
95. Gunther, E. C., Stone, D. J., Gerwien, R. W., Bento, P. & Heyes, M. P. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl Acad. Sci. USA 100, 9608-9613 (2003).
96. Agid, O. et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol. Psychiatry 4, 163-172 (1999).
97. Maier, S. F. Learned helplessness and animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 435-446 (1984).
98. Seligman, M. E. & Beagley, G. Learned helplessness in the rat. J. Comp. Physiol. Psychol. 88, 534-541 (1975).
99. Vollmayr, B. & Henn, F. A. Learned helplessness in the rat: improvements in validity and reliability: Brain Res. Brain Res. Protoc. 8, 1-7 (2001).
100. Porsolt, R. D., Bertin, A. & Jalfre, M. 'Behavioural despair' in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 51, 291-294 (1978).
101. West, A. P. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 863-877 (1990).
102. Porsolt, R. D. et al. Use of the automated tail suspension test for the primary screening of psychotropic agents. Arch. Int. Pharmacodyn. Ther. 288, 11-30 (1987).
103. Bai, F., Li, X., Clay, M., Lindstrom, T. & Skolnick, P. Intra- and interstrain differences in models of 'behavioral despair'. Pharmacol. Biochem. Behav. 70, 187-192 (2001).
104. Mayorga, A. J. & Lucki, I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl) 155, 110-112 (2001).
105. Shizgal, P. Toward a cellular analysis of intracranial self-stimulation: contributions of collision studies. Neurosci. Biobehav. Rev. 13, 81-90 (1989).
106. Matthews, K., Forbes, N. & Reid, I. C. Sucrose consumption as an hedonic measure following chronic unpredictable mild stress. Physiol. Behav. 57, 241-248 (1995).
107. Forbes, N. F., Stewart, C. A., Matthews, K. & Reid, I. C. Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol. Behav. 60, 1481-1484 (1996).
108. Harris, R. B., Zhou, J., Youngblood, B. D., Smagin, G. N. & Ryan, D. H. Failure to change exploration or saccharin preference in rats exposed to chronic mild stress. Physiol. Behav. 63, 91-100 (1997).
109. van der Kooy, D. in Methods of Assessing the Reinforcing Properties of Abused Drugs (ed. Bozarth, M. A.) 229-240 (Springer, New York, 1987).
110. Kelly, J. P., Wrynn, A. S. & Leonard, B. E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74, 299-316 (1997).
111. Hozumi, S. et al. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav. Brain Res. 138, 9-15 (2003).
112. Katz, R. J., Roth, K. A. & Carroll, B. J. Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neurosci. Biobehav. Rev. 5, 247-251 (1981).
113. Willner, P., Muscat, R. & Papp, M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16, 525-534 (1992).
114. Kokkinidis, L., Zacharko, R. M. & Anisman, H. Amphetamine withdrawal: a behavioral evaluation. Life Sci. 38, 1617-1623 (1986).
115. Anraku, T., Ikegaya, Y., Matsuki, N. & Nishiyama, N. Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test. Psychopharmacology (Berl) 157, 217-220 (2001).
116. Cryan, J. F., Hoyer, D. & Markou, A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol. Psychiatry 54, 49-58 (2003).
117. Matthews, K. & Robbins, T. W. Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat. Neurosci. Biobehav. Rev. 27, 45-55 (2003).
118. Ladd, C. O., Owens, M. J. & Nemeroff, C. B. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 137, 1212-1218 (1996).
119. Pryce, C. R. & Felden, J. Long-term neurobehavioural impact of the postnatal environment in rats: manipulations, effects and mediating mechanisms. Neurosci. Biobehav. Rev. 27, 57-71 (2003).
120. Vogel, G., Neill, D., Hagler, M. & Kors, D. A new animal model of endogenous depression: a summary of present findings. Neurosci. Biobehav. Rev. 14, 85-91 (1990).
121. Overstreet, D. H. The Flinders sensitive line rats: a genetic animal model of depression. Neurosci. Biobehav. Rev. 17, 51-68 (1993).
122. Overstreet, D. H. Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav. Genet. 32, 335-348 (2002).
123. Rezvani, A. H., Parsian, A. & Overstreet, D. H. The Fawn-Hooded (FH/Wjd) rat: a genetic animal model of comorbid depression and alcoholism. Psychiatr. Genet. 12, 1-16 (2002).
124. El Yacoubi, M. et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc. Natl Acad. Sci. USA 100, 6227-6232 (2003).
125. Vaugeois, J. M., Odievre, C., Loisel, L. & Costentin, J. A genetic mouse model of helplessness sensitive to imipramine. Eur. J. Pharmacol. 316, R1-R2 (1996).
126. 1A knockout: an animal model of anxiety-related disorder. Proc. Natl Acad. Sci. USA 95, 14476-14481 (1998).
127. 1A receptor mutant mice. Proc. Natl Acad. Sci. USA 95, 15049-15054 (1998).
128. 1A receptor. Proc. Natl Acad. Sci. USA 95, 10734-10739 (1998).
129. 1A knock-out mice. J. Neurosci. 22, 4686-4692 (2002).
130. Mayorga, A. J. et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. J. Pharmacol. Exp. Ther. 298, 1101-1107 (2001).
131. Knobelman, D. A., Hen, R., Blendy, J. A. & Lucki, I. Regional patterns of compensation following genetic deletion of either 5-hydroxytryptamine(1A) or 5-hydroxytryptamine(1B) receptor in the mouse. J. Pharmacol. Exp. Ther. 298, 1092-1100 (2001).
132. Knobelman, D. A., Hen, R. & Lucki, I. Genetic regulation of extracellular serotonin by 5-hydroxytryptamined(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse. J. Pharmacol. Exp. Ther. 298, 1083-1091 (2001).
133. 1B receptor knockout mice. Eur. J. Pharmacol. 439, 93-100 (2002).
134. 1B receptor knock-out mice. Eur. J. Pharmacol. 443, 99-104 (2002).
135. Holmes, A., Yang, R. J., Murphy, D. L. & Crawley, J. N. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter Neuropsychopharmacology 27, 914-923 (2002).
136. 1A binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291, 999-1007 (1999).
137. Gobbi, G., Murphy, D. L., Lesch, K. & Blier, P. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296, 987-995 (2001).
138. 1A receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J. Neurosci. 21, 2178-2185 (2001).
139. Cryan, J. F. et al. Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J. Pharmacol. Exp. Ther. 298, 651-657 (2001).
140. 2A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 21, 4875-4882 (2001).
141. 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry 4, 443-452 (1999).
142. Haller, J. et al. Behavioral responses to social stress in noradrenaline transporter knockout mice: effects on social behavior and depression. Brain Res. Bull. 58, 279-284 (2002).
143. Evrard, A. et al. Altered regulation of the 5-HT system in the brain of MAO-A knock-out mice. Eur J. Neurosci. 15, 841-851 (2002).
144. Cases, O. et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 268, 1763-1766 (1995).
145. Grimsby, J. et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nature Genet. 17, 206-210 (1997).
146. Filliol, D. et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nature Genet. 25, 195-200 (2000).
147. Stork, O. et al. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res. 865, 45-58 (2000).
148. Schuler, V. et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31, 47-58 (2001).
149. Miyamoto, Y. et al. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit. J. Neurosci. 22, 2335-2342 (2002).
150. Cryan, J. F. et al. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGIuR7. Eur J. Neurosci. 17, 2409-2417 (2003).
151. Rupniak, N. M. et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol. 12, 497-508 (2001).
152. Santarelli, L., Gobbi, G., Blier, P. & Hen, R. Behavioral and physiologic effects at genetic or pharmacologic inactivation of the substance P receptor (NK1). J. Clin. Psychiatry 63 (Suppl. 11), 11-17 (2002).
153. 1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 21, 8188-8197 (2001).
154. Bilkei-Gorzo, A., Racz, I., Michel, K. & Zimmer, A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J. Neurosci. 22, 10046-10052 (2002).
155. Montkowski, A. et al. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J. Neuroendocrinol. 7, 841-845 (1995).
156. Groenink, L. et al. HPA axis dysregulation in mice over-expressing corticotropin releasing hormone. Biol. Psychiatry 51, 875-881 (2002).
157. van Gaalen, M. M., Stenzel-Poore, M. P., Holsboer, F. & Steckler, T. Effects of transgenic overproduction of CRH an anxiety-like behaviour. Eur J. Neurosci. 15, 2007-2015 (2002).
158. Bale, T. L. & Vale, W. W. Increased depression-like behaviors in corticotropin-releasing factor receptor 2-deficient mice: sexually dichotomous responses. J. Neurosci. 23, 5295-5301 (2003).
159. Holmes, A., Yang, R. J. & Crawley, J. N. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J. Mol. Neurosci. 18, 151-165 (2002).
160. Yamada, K. et al. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-α gene: implications for emotional behavior. J. Neuroimmunol. 111, 131-138 (2000 ).
161. Calapai, G. et al. Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34 (Suppl. 1), S8-S10 (2001).
162. Svenningsson, P. et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl Acad. Sci. USA 99, 3182-3187 (2002).
163. Zhang, H. T. et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27, 587-595 (2002).
164. Cao, B. J. & Li, Y. Reduced anxiety- and depression-like behaviors in Emx1 homozygous mutant mice. Brain Res 937, 32-40 (2002).
165. Saarelainen, T. et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23, 349-357 (2003).
166. Rahman, Z. et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38, 941-952 (2003).
167. 2A receptor knockout mice are partially protected against drug-induced catalepsy. Neuroreport 12, 983-986 (2001).
168. Drago, J., McColl, C. D., Horne, M. K., Finkelstein, D. I. & Ross, S. A. Neuronal nicotinic receptors: insights gained from gene knockout and knockin mutant mice. Cell. Mol. Life Sci. 60, 1267-1280 (2003).
169. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379-387 (2002).
170. Gavioli, E. C. et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J. Neurosci. 17, 1987-1990 (2003).
171. Tschenett, A. et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J. Neurosci. 18, 143-148 (2003).
172. 5 receptor null mutant mice. Behav. Neurosci. 115, 1129-1144 (2001).
173. Okuyama, S., Sakagawa, T., Sugiyama, F., Fukamizu, A. & Murakami, K. Reduction of depressive-like behavior in mice lacking angiotensinogen. Neurosci. Lett. 261, 167-170 (1999).
174. Stork, O. et al. Recovery of emotional behaviour in neural cell adhesion molecule (NCAM) null mutant mice through transgenic expression of NCAM180. Eur J. Neurosci. 12, 3291-3306 (2000).
175. Cheeta, S., Ruigt, G., van Proosdij, J. & Willner, P. Changes in sleep architecture following chronic mild stress. Biol. Psychiatry 41, 419-427 (1997).
176. 2C receptor mutant mice. Diabetes 52, 315-320 (2003).
177. Ballard, T. M. et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity, J. Neurosci. 22, 6713-6723 (2002).
178. Haller, J. & Bakos, N. Stress-induced social avoidance: a new model of stress-induced anxiety? Physiol. Behav. 77, 327-332 (2002).
179. Dixon, A. K., Huber, C. & Lowe, D. A. Clozapine promotes approach-oriented behavior in male mice. J. Clin. Psychiatry 55 (Suppl. B), 4-7 (1994).
180. Dunn, A. L. & Crnic, L. S. Repeated injections of interferon-α A/D in Balb/c mice: behavioral effects. Brain Behav. Immun. 7, 104-111 (1993).
181. Grippo, A. J., Beltz, T. G. & Johnson, A. K. Behavioral and cardiovascular changes in the chronic mild stress model of depression. Physiol. Behav. 78, 703-710 (2003).
182. van Gaalen, M. M., Stenzel-Poore, M., Holsboer, F. & Steckler, T. Reduced attention in mice overproducing corticotropin-releasing hormone. Behav. Brain Res. 142, 69-79 (2003).
183. Contarino, A. et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835, 1-9 (1999).
184. Estape, N. & Steckler, T. Cholinergic blockade impairs performance in operant DNMTP in two inbred strains of mice. Pharmacol. Biochem. Behav. 72, 319-334 (2002).
185. Maccari, S. et al. Prenatal stress and long-term consequences: implications of glucocorticoid hormones. Neurosci. Biobehav. Rev. 27, 119-127 (2003).
186. 1A receptor antagonist, WAY-100635. Behav. Pharmacol. 8, 585-606 (1997).
187. Dunn, A. J. & Swiergiel, A. H. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation 9, 163-169 (2001).
188. Benedetti, F. et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipular depression. Am. J. Psychiatry 156, 1450-1452 (1999).
189. Kim, D. K. et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11, 215-219 (2000).
190. Pollock, B. G. et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590 (2000).
191. Zanardi, R., Benedetti, F., Di Bella, D., Catalano, M. & Smeraldi, E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 20, 105-107 (2000).
192. Zill, P. et al. Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment. Neurorepont 11, 1893-1897 (2000).
193. Mundo, E., Walker, M., Cate, T., Macciardi, F. & Kennedy, J. L. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch. Gen. Psychiatry 58, 539-544 (2001).
194. Serretti, A. et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 6, 586-592 (2001).
195. Zanardi, R. et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 50, 323-330 (2001).
196. Baghai, T. C. et al. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol. Psychiatry 6, 258-259 (2001).
197. Serretti, A. et al. Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am. J. Med. Genet. 81, 127-130 (1998).
198. Serretti, A. et al. No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res. 104, 195-203 (2001).
199. Cusin, C. et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int. J. Neuropsychopharmacol. 5, 27-35 (2002).
200. Roberts, R. L., Joyce, P. R., Mulder, R. T., Begg, E. J. & Kennedy, M. A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2, 191-196 (2002).
201. Murphy, G. M., Jr, Kremer, C., Rodrigues, H. E. & Schatzberg, A. F. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 160, 1830-1835 (2003).
202. Lerer, B. & Macciardi, F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int. J. Neuropsychopharmacol. 5, 255-275 (2002).
203. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Washington, DC, 1994).
204. Wong, M.-L. & Licinio, J. Research and treatment approaches to depression. Nature Rev. Neurosci. 2, 343-351 (2001).
205. Willner, P. & Mitchell, P. J. The validity of animal models of predisposition to depression. Behav. Pharmacol. 13, 169-188 (2002).